Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1972 1
1974 1
1975 2
1978 1
1980 2
1981 2
1982 1
1987 3
1989 1
1991 1
1994 4
1995 2
1996 1
1997 2
1998 14
1999 1
2000 4
2001 4
2002 3
2003 6
2004 12
2005 14
2006 3
2007 14
2008 13
2009 21
2010 20
2011 27
2012 34
2013 46
2014 51
2015 48
2016 54
2017 62
2018 57
2019 75
2020 104
2021 137
2022 116
2023 111
2024 59

Text availability

Article attribute

Article type

Publication date

Search Results

1,007 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Yastrzemski
Page 1
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.
Rajkumar SV. Rajkumar SV. Am J Hematol. 2022 Aug;97(8):1086-1107. doi: 10.1002/ajh.26590. Epub 2022 May 23. Am J Hematol. 2022. PMID: 35560063 Free PMC article.
In high-risk patients, daratumumab, bortezomib, lenalidomide, dexamethasone (Dara-VRd) is an alternative to VRd. Selected standard-risk patients can collect stem cells, get additional cycles of induction therapy, and delay transplant until first relapse. ...
In high-risk patients, daratumumab, bortezomib, lenalidomide, dexamethasone (Dara-VRd) is an alternative to VRd. Selected standard-ri …
Diagnosis and Treatment of AL Amyloidosis.
Palladini G, Milani P. Palladini G, et al. Drugs. 2023 Feb;83(3):203-216. doi: 10.1007/s40265-022-01830-z. Epub 2023 Jan 18. Drugs. 2023. PMID: 36652193 Review.
The combination of daratumumab, cyclophosphamide, bortezomib and dexamethasone (dara-CyBorD) is the current standard of care. Autologous stem cell transplant is performed in eligible patients, especially those who do not attain a satisfactory response to dara-CyBorD …
The combination of daratumumab, cyclophosphamide, bortezomib and dexamethasone (dara-CyBorD) is the current standard of care. Autolog …
Multiple myeloma: 2020 update on diagnosis, risk-stratification and management.
Rajkumar SV. Rajkumar SV. Am J Hematol. 2020 May;95(5):548-567. doi: 10.1002/ajh.25791. Am J Hematol. 2020. PMID: 32212178 Free article. Review.
In high-risk patients, daratumumab, bortezomib, lenalidomide, dexamethasone (Dara-VRd) is an alternative to VRd. Selected standard risk patients can get additional cycles of induction, and delay transplant until first relapse. ...
In high-risk patients, daratumumab, bortezomib, lenalidomide, dexamethasone (Dara-VRd) is an alternative to VRd. Selected standard ri …
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.
Palladini G, Kastritis E, Maurer MS, Zonder J, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Bumma N, Kaufman JL, Medvedova E, Kovacsovics T, Rosenzweig M, Sanchorawala V, Qin X, Vasey SY, Weiss BM, Vermeulen J, Merlini G, Comenzo RL. Palladini G, et al. Blood. 2020 Jul 2;136(1):71-80. doi: 10.1182/blood.2019004460. Blood. 2020. PMID: 32244252 Free PMC article. Clinical Trial.
We report results of the 28-patient safety run-in. Patients received subcutaneous daratumumab (DARA SC) weekly in cycles 1 to 2, every 2 weeks in cycles 3 to 6, and every 4 weeks thereafter for up to 2 years. ...Patients received a median of 16 (range, 1-23) treatment cycl …
We report results of the 28-patient safety run-in. Patients received subcutaneous daratumumab (DARA SC) weekly in cycles 1 to 2, ever …
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.
Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, Silbermann R, Dhakal B, Bal S, Giri S, D'Souza A, Hall A, Hardwick P, Omel J, Cornell RF, Hari P, Callander NS. Costa LJ, et al. J Clin Oncol. 2022 Sep 1;40(25):2901-2912. doi: 10.1200/JCO.21.01935. Epub 2021 Dec 13. J Clin Oncol. 2022. PMID: 34898239 Clinical Trial.
PURPOSE: The MASTER trial combined daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) in newly diagnosed multiple myeloma (NDMM), using minimal residual disease (MRD) by next-generation sequencing (NGS) to inform the use and duration of Dara-KRd po …
PURPOSE: The MASTER trial combined daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) in newly diagnosed multiple m …
Cell Death in Liver Diseases: A Review.
Shojaie L, Iorga A, Dara L. Shojaie L, et al. Int J Mol Sci. 2020 Dec 18;21(24):9682. doi: 10.3390/ijms21249682. Int J Mol Sci. 2020. PMID: 33353156 Free PMC article. Review.
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma.
Usmani SZ, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, Hungria V, Korenkova S, Bahlis NJ, Flogegard M, Bladé J, Moreau P, Kaiser M, Iida S, Laubach J, Magen H, Cavo M, Hulin C, White D, De Stefano V, Lantz K, O'Rourke L, Heuck C, Delioukina M, Qin X, Nnane I, Qi M, Mateos MV. Usmani SZ, et al. Haematologica. 2022 Oct 1;107(10):2408-2417. doi: 10.3324/haematol.2021.279459. Haematologica. 2022. PMID: 35354247 Free PMC article. Clinical Trial.
The overall response rate was 43.7% for DARA SC and 39.8% for DARA IV. The maximum mean (standard deviation [SD]) trough concentration (cycle 3, day 1 pre-dose) of serum DARA was 581 (SD, 315) mug/mL for DARA SC and 496 (SD, 231) mug/mL for DARA …
The overall response rate was 43.7% for DARA SC and 39.8% for DARA IV. The maximum mean (standard deviation [SD]) trough conce …
Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma.
Kaiser MF, Hall A, Walker K, Sherborne A, De Tute RM, Newnham N, Roberts S, Ingleson E, Bowles K, Garg M, Lokare A, Messiou C, Houlston RS, Jackson G, Cook G, Pratt G, Owen RG, Drayson MT, Brown SR, Jenner MW. Kaiser MF, et al. J Clin Oncol. 2023 Aug 10;41(23):3945-3955. doi: 10.1200/JCO.22.02567. Epub 2023 Jun 14. J Clin Oncol. 2023. PMID: 37315268
METHODS: Transplant-eligible all-comers NDMM patients were profiled for UHiR disease, defined by presence of 2 genetic risk markers t(4;14)/t(14;16)/t(14;20), del(1p), gain(1q), and del(17p), and/or SKY92 gene expression risk signature. Patients with UHiR MM/PCL were offered trea …
METHODS: Transplant-eligible all-comers NDMM patients were profiled for UHiR disease, defined by presence of 2 genetic risk markers t(4;14)/ …
Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update.
Bazarbachi AH, Al Hamed R, Malard F, Bazarbachi A, Harousseau JL, Mohty M. Bazarbachi AH, et al. Blood Cancer J. 2022 Mar 28;12(3):47. doi: 10.1038/s41408-022-00645-1. Blood Cancer J. 2022. PMID: 35347107 Free PMC article. Review.
In fact, the updated 2021 European Haematology Association (EHA) and European Society for Medical Oncology (ESMO) clinical practice guidelines recommend the use of either lenalidomide-Vd (VRd), or daratumumab-thalidomide-Vd (Dara-VTd) as first-line options for transplant-e …
In fact, the updated 2021 European Haematology Association (EHA) and European Society for Medical Oncology (ESMO) clinical practice guidelin …
1,007 results